Exakte Wirkstoffkennungen und zitierbare Passagen zu Wechselwirkungen, Gegenanzeigen und Nebenwirkungen.
Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
Antiparasitics
Praziquantel Significant decrease in plasma Concomitant use with
concentrations of praziquantel with praziquantel is not recommended.
risk of treatment failure due to In case the combination is needed,
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
14
Medicinal product by Effects on drug levels Recommendation concerning
therapeutic areas Mean percent change in AUC, co-administration with
(dose) Cmax, Cmin with confidence efavirenz
intervals if availablea
(mechanism)
increased hepatic metabolism by an increased dose of praziquantel
efavirenz. could be considered.
ACID-REDUCING AGENTS
Aluminium hydroxide- Neither aluminium/magnesium Co-administration of efavirenz
magnesium hydroxide- hydroxide antacids nor famotidine with medicinal products that alter
simethicone antacid/efavirenz altered the absorption of efavirenz. gastric pH would not be expected
(30 ml single dose/400 mg single to affect efavirenz absorption.
dose)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
9
Medicinal product by Expected effect on drug levels Recommendation for co-
therapeutic area administration
Telithromycin Telithromycine: Not recommended.
Clarithromycin AUC: ↑ 2-fold Contraindicated in patients with
Cmax: ↑1.5-fold severe renal impairment due to the
Potential ↑in plasma concentrations of risk of QT interval prolongation and
clarithromycin serious hepatic adverse reactions (see
section 4.3).
Isavuconazole AUC: ↑ 5-fold Not recommended due to increased
Cmax: ↑ 1.1 -fold risk of isavuconazole adverse
reactions, please consult
isavuconazole SmPC
Praziquantel ↑in plasma concentrations of Careful monitoring.
praziquantel have been observed Dose adjustment of praziquantel
may be required.
Antimigraine Drugs
Ergots alkaloids such as Potential ↑in plasma concentrations of Contraindicated due to the increased
dihydroergotamine, ergot alkaloids risk of ergotism and other serious
ergometrine vasospastic adverse reactions (see
(ergonovine), section 4.3).
ergotamine,
methylergometrine
(methylergonovine)
Eletriptan Eletriptan: Not recommended.
AUC: ↑ 5.9-fold
Cmax: ↑ 2.7-fold
Antineoplastics
Irinotecan Irinotecan: Contraindicated due to an alteration
AUC: ↑ 2.1-fold of the metabolism of this medicinal
product (see section 4.3).
Sunitinib Sunitinib Not recommended due to the risk of
Dasatinib AUC: ↑ 1.5-fold increased exposure to these medicinal
Lapatinib Cmax: ↑ 1.5-fold products and QT prolongation.
Nilotinib Lapatinib:
Erlotinib AUC: ↑ 3.6-fold
Dabrafenib Nilotinib:
Cabozantinib AUC: ↑ 3.0-fold
Erlotinib:
AUC: ↑ 1.9-fold
Cmax: ↑ 1.7-fold
Dasatinib
↑in plasma concentrations of
Dasatinib have been observed
Dabrafenib
AUC: ↑ 1.7-fold
Cmax: ↑ 1.3-fold
Cabozantinib
AUC: ↑ 1.4-fold
Cmax: ↔
Ibrutinib Ibrutinib: Not recommended as it may increase
AUC: ↑ 24-fold ibrutinib-related toxicity.
Cmax: ↑ 29-fold
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Version 2025-05-05T12:00:00Z · SHA-256 1463d2e081bcaa454cdfd6129ad3b8e03e3df9233f9d0704cfceba71c89c59b5 · Passage 03def5869df8cb542da23a60d098a55dd2a7a8fe93c7c4d29a7dfa3bc81a0b64 · Zeichen 11575–15074 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.